These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 20673009)

  • 1. In planta production of plant-derived and non-plant-derived adjuvants.
    Granell A; Fernández del-Carmen A; Orzáez D
    Expert Rev Vaccines; 2010 Aug; 9(8):843-58. PubMed ID: 20673009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal immunization using recombinant plant-based oral vaccines.
    Streatfield SJ
    Methods; 2006 Feb; 38(2):150-7. PubMed ID: 16431131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant activities of saponins from traditional Chinese medicinal herbs.
    Song X; Hu S
    Vaccine; 2009 Aug; 27(36):4883-90. PubMed ID: 19559122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plant-based anti-HIV-1 strategies: vaccine molecules and antiviral approaches.
    Scotti N; Buonaguro L; Tornesello ML; Cardi T; Buonaguro FM
    Expert Rev Vaccines; 2010 Aug; 9(8):925-36. PubMed ID: 20673014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New generation of mucosal adjuvants for the induction of protective immunity.
    Yuki Y; Kiyono H
    Rev Med Virol; 2003; 13(5):293-310. PubMed ID: 12931340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
    Holmgren J; Adamsson J; Anjuère F; Clemens J; Czerkinsky C; Eriksson K; Flach CF; George-Chandy A; Harandi AM; Lebens M; Lehner T; Lindblad M; Nygren E; Raghavan S; Sanchez J; Stanford M; Sun JB; Svennerholm AM; Tengvall S
    Immunol Lett; 2005 Mar; 97(2):181-8. PubMed ID: 15752556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria.
    van Roosmalen ML; Kanninga R; El Khattabi M; Neef J; Audouy S; Bosma T; Kuipers A; Post E; Steen A; Kok J; Buist G; Kuipers OP; Robillard G; Leenhouts K
    Methods; 2006 Feb; 38(2):144-9. PubMed ID: 16414272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
    Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
    Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heteropentameric cholera toxin B subunit chimeric molecules genetically fused to a vaccine antigen induce systemic and mucosal immune responses: a potential new strategy to target recombinant vaccine antigens to mucosal immune systems.
    Harakuni T; Sugawa H; Komesu A; Tadano M; Arakawa T
    Infect Immun; 2005 Sep; 73(9):5654-65. PubMed ID: 16113283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in saponin-based adjuvants.
    Sun HX; Xie Y; Ye YP
    Vaccine; 2009 Mar; 27(12):1787-96. PubMed ID: 19208455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Starch microparticles as vaccine adjuvant.
    Rydell N; Stertman L; Sjöholm I
    Expert Opin Drug Deliv; 2005 Sep; 2(5):807-28. PubMed ID: 16296780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plant glycans: friend or foe in vaccine development?
    Bosch D; Schots A
    Expert Rev Vaccines; 2010 Aug; 9(8):835-42. PubMed ID: 20673008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PharmaPlant: the new frontier in vaccines. Forward.
    Buonaguro FM; Butler-Ransohoff JE
    Expert Rev Vaccines; 2010 Aug; 9(8):805-7. PubMed ID: 20673004
    [No Abstract]   [Full Text] [Related]  

  • 14. Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles.
    O'Hagan DT; Ott GS; Van Nest G
    Mol Med Today; 1997 Feb; 3(2):69-75. PubMed ID: 9060004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biotechnology approaches to produce potent, self-adjuvanting antigen-adjuvant fusion protein subunit vaccines.
    Moyle PM
    Biotechnol Adv; 2017; 35(3):375-389. PubMed ID: 28288861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
    Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW
    Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant.
    Holmgren J; Czerkinsky C; Lycke N; Svennerholm AM
    Am J Trop Med Hyg; 1994; 50(5 Suppl):42-54. PubMed ID: 8203723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization.
    Akhiani AA; Stensson A; Schön K; Lycke N
    Scand J Immunol; 2006 Feb; 63(2):97-105. PubMed ID: 16476008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological adjuvants and their modes of action.
    Allison AC
    Arch Immunol Ther Exp (Warsz); 1997; 45(2-3):141-7. PubMed ID: 9597079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.